Volume 1, Issue 1 (11-2013)                   JoMMID 2013, 1(1): 27-35 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Dobakhti F, Khalili G, Mahmoudzadeh Niknam H, Khaze V, Partovi F, Naghibi Mahmoodabadi T et al . Role of imiquimod as adjuvant for vaccination against Leishmania major infection in BALB/c mice. JoMMID. 2013; 1 (1) :27-35
URL: http://jommid.pasteur.ac.ir/article-1-37-en.html
Immunology Department, Pasteur Institute of Iran, Tehran, Iran
Abstract:   (16773 Views)

Various adjuvants in combination with different antigens have been utilized as a vaccine candidate against leishmaniasis. However, the search for ideal adjuvants is still pursued due to the inefficiencies of current compounds. In the present study, the effect of imiquimod, as an adjuvant, is studied with soluble Leishmania antigens (SLA) in BALB/c mice. Four groups of mice were immunized with SLA, SLA plus imiquimod, SLA plus BCG, and PBS as control. Immunized mice received a boosting dose of SLA after 15 days. All groups were challenged with Leishmania major (L. major) promastigotes 2 weeks after the booster immunization. Our results showed that strong TH1 responses were induced in groups of SLA plus imiquimod as well as SLA plus BCGafter immunization. These responses included smaller footpad thickness, lower parasite load in lymph node, and higher proliferative response of lymph node cells to SLA, higher levels of interferon &gamma in culture supernatant of lymph node cells, and higher levels of IgG, and IgG2a in sera. The data supports the possibility of using imiquimod as a suitable adjuvant in leishmania vaccination.

Full-Text [PDF 278 kb]   (1770 Downloads)    
Type of Study: Original article |
Received: 2013/06/17 | Accepted: 2013/08/20 | Published: 2013/12/22

Add your comments about this article : Your username or Email:

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.